0001140361-23-004345.txt : 20230203 0001140361-23-004345.hdr.sgml : 20230203 20230203083028 ACCESSION NUMBER: 0001140361-23-004345 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230202 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bionano Genomics, Inc. CENTRAL INDEX KEY: 0001411690 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 261756290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38613 FILM NUMBER: 23583812 BUSINESS ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 888-7600 MAIL ADDRESS: STREET 1: 9540 TOWNE CENTRE DRIVE STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Bionano Genomics, Inc DATE OF NAME CHANGE: 20190308 FORMER COMPANY: FORMER CONFORMED NAME: BioNano Genomics, Inc DATE OF NAME CHANGE: 20120703 FORMER COMPANY: FORMER CONFORMED NAME: BioNanomatrix Inc DATE OF NAME CHANGE: 20070906 8-K 1 brhc10047533_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2023
Bionano Genomics, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-38613
26-1756290
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

9540 Towne Centre Drive, Suite 100
    
San Diego, California
  
92121
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (858) 888-7600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
BNGO
The Nasdaq Stock Market LLC
Warrants to purchase Common Stock
BNGOW
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.
Results of Operations and Financial Condition.

As previously announced on January 5, 2022, Bionano Genomics, Inc. (the “Company”), expects to report full year 2022 total revenue in the range of $27.7 million and $28.0 million. On February 2, 2023, in connection with its previously announced Strategy Day, the Company disclosed the anticipated breakdown and geographic concentration of this total revenue, as follows:
 
•
The breakdown of full year 2022 revenue is expected to be approximately: 57% revenue generated through sales of systems and consumables; 21% revenue generated through licensing of software for the analysis, interpretation and reporting of genomic data, including the Company’s NxClinicalTM software; and 22% generated from revenue from the sale of diagnostic testing services, services performed related to customer sample evaluations, software-as-a-service for the analysis, interpretation and reporting of genomic data, as well as warranty and other service-based revenue, including support, repair and maintenance services.
 
•
Full year 2022 revenue by geographic region (based on the customer’s billing address) on a disaggregated basis is expected to be approximately 50% Americas (North America and South America), 17% Asia Pacific (China, Japan, South Korea, Singapore, India and Australia), and 33% EMEA (Europe, the Middle East and Africa).

These expected results are preliminary and unaudited, are based on the Company’s initial review of its results for the year ended December 31, 2022 and are subject to revision based upon the Company’s year-end closing procedures and the completion and external audit of its year-end financial statements. Actual results may differ from these preliminary unaudited results as a result of the completion of year-end closing procedures, final adjustments and other developments arising between now and the time that the Company’s financial results are finalized, and such changes could be material. In addition, these preliminary unaudited results are not a comprehensive statement of the Company’s financial results for the year ended December 31, 2022, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the Company’s results for any future period.

Item 8.01.
Other Events.

On February 2, 2023, in connection with its previously announced Strategy Day, the Company provided the following updated information related to its estimated total addressable market. The Company’s target markets include an estimated 10,000 labs and 1,400 therapeutics companies. The Company expects optical genome mapping (“OGM”) adoption primarily in cytogenomics and discovery research and believes cell bioprocessing quality control could be an additional market opportunity. The Company estimates that there are 10,000 cytogenetic and discovery research labs on a worldwide basis that analyze up to 10 million samples annually and when taken together with the cell bioprocessing quality control opportunity, the Company estimates a total potential market opportunity of up to $10 billion annually. Within that total potential market opportunity, the Company estimates the potential future market opportunity with cell bioprocessing quality control to represent a $3 billion of opportunity for OGM annually.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered “forward-looking statements,” including, but not limited to, statements regarding the Company’s preliminary expected full year 2022 revenue, including the breakdown and geographical concentration of such revenue; the size of the Company’s target markets and specific markets driving OGM adoption; and the Company’s estimates and supporting assumptions regarding its estimated total addressable market. Words such as “anticipate,” “expect,” “preliminary,” “opportunity,” “estimate,” “approximate,” “believe,” “potential,” “future” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Forward-looking statements are based on the Company’s current expectations and what the Company believes to be reasonable assumptions based on information currently available to it, and are subject to risks and uncertainties. Such risks and uncertainties may cause actual results to differ materially from these forward-looking statements. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and geopolitical and macroeconomic developments, including the Ukraine-Russia conflict and the COVID-19 pandemic; completion of Company’s year-end closing procedures and the completion and external audit of its year-end financial statements; the timing and amount of revenue the Company is able to recognize in a given fiscal period; changes in market data, customer demand, product pricing and other factors impacting the Company’s ability to generate revenue; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in the Company’s strategic and commercial plans; the Company’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; and the ability of target customers to obtain funding to support adoption or continued use of the Company’s technologies. Additional factors that could cause actual results to differ materially from those stated or implied by the Company’s forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including in the section captioned “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. These forward-looking statements represent the Company’s judgment as of the filing date hereof. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 3, 2023
Bionano Genomics, Inc.
   
 
By:
/s/ R. Erik Holmlin, Ph.D.
   
R. Erik Holmlin, Ph.D.
   
President and Chief Executive Officer
(Principal Executive Officer)


EX-101.SCH 2 bngo-20230202.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 bngo-20230202_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 bngo-20230202_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Warrants to purchase Common Stock [Member] EX-101.PRE 5 bngo-20230202_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Feb. 02, 2023
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 02, 2023
Entity File Number 001-38613
Entity Registrant Name Bionano Genomics, Inc.
Entity Central Index Key 0001411690
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-1756290
Entity Address, Address Line One 9540 Towne Centre Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 888-7600
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol BNGO
Security Exchange Name NASDAQ
Warrants to purchase Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Warrants to purchase Common Stock
Trading Symbol BNGOW
Security Exchange Name NASDAQ
XML 7 brhc10047533_8k_htm.xml IDEA: XBRL DOCUMENT 0001411690 2023-02-02 2023-02-02 0001411690 us-gaap:CommonStockMember 2023-02-02 2023-02-02 0001411690 bngo:WarrantsToPurchaseCommonStockMember 2023-02-02 2023-02-02 false 0001411690 NASDAQ NASDAQ 8-K 2023-02-02 Bionano Genomics, Inc. DE 001-38613 26-1756290 9540 Towne Centre Drive Suite 100 San Diego CA 92121 858 888-7600 false false false false Common Stock, $0.0001 par value per share BNGO Warrants to purchase Common Stock BNGOW false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 23 1 false 2 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bionanogenomics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - brhc10047533_8k.htm 11 brhc10047533_8k.htm bngo-20230202.xsd bngo-20230202_def.xml bngo-20230202_lab.xml bngo-20230202_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10047533_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bngo-20230202_def.xml" ] }, "inline": { "local": [ "brhc10047533_8k.htm" ] }, "labelLink": { "local": [ "bngo-20230202_lab.xml" ] }, "presentationLink": { "local": [ "bngo-20230202_pre.xml" ] }, "schema": { "local": [ "bngo-20230202.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 35, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bngo", "nsuri": "http://bionanogenomics.com/20230202", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10047533_8k.htm", "contextRef": "c20230202to20230202", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://bionanogenomics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10047533_8k.htm", "contextRef": "c20230202to20230202", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bngo_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase Common Stock [Member]" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://bionanogenomics.com/20230202", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://bionanogenomics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001140361-23-004345-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-004345-xbrl.zip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
  •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